Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of…
Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland Ginkgo provides an update on its second quarter financial results and its continued efforts to scale Nebu
How this was made
The 30-second read
Why it matters
Traders can reassess DNA’s near-term burn profile and execution risk based on the reported revenue contraction, adjusted EBITDA loss, and reaffirmed 2026 cash-burn range, alongside evidence of scaling and new service/customer traction.
Market read
Primary quarterly disclosure with hard financial datapoints and a reaffirmed cash-burn outlook, plus named government contract wins and early customer traction for ADME-One.
What to watch
The excerpt highlights contract and lab build wins (NSF cloud lab nodes, MIT/Caltech/Northwestern/UMD) and a new ADME-One service with 17 customers in 6 weeks, which could offset near-term financial deterioration if investors weight commercial traction over quarterly losses.
Background
SEC Form 8-K Item 2.02 with Exhibit 99.1 summarizing Ginkgo’s Q2 2026 results and business updates, including Nebula scaling and government contract activity.
Ticker impact
Ginkgo reported Q2 2026 revenue of $20M (down 48% YoY) and GAAP net loss of ($57)M, citing program rationalization from restructuring.
Likely downside or volatility if investors focus on revenue contraction and widening adjusted EBITDA losses, partially offset by $302M cash and contract wins.
This is a primary 8-K earnings-style disclosure with multiple hard datapoints (revenue, losses, cash balance, and cash-burn outlook). However, the excerpt does not include consensus comparisons or guidance changes beyond reaffirmation, limiting certainty on magnitude/direction.
Market effects
Reinforces demand narrative for autonomous lab infrastructure and government-funded cloud lab nodes, which may support sentiment toward synthetic biology tools and lab automation peers.
Limited direct regional read-through beyond Boston-based Nebula scaling and U.S. federal/NSF contracting.
Primarily U.S.-focused government and onshoring story; limited immediate global impact from the excerpt.
Counterpoint
Revenue decline may reflect restructuring timing rather than demand collapse, while cash balance ($302M) and scaling Nebula could improve operating leverage later in 2026.
Key entities
- companyGinkgo Bioworks Holdings, Inc.
Reports Q2 2026 financial results, restructuring-driven program rationalization, Nebula scaling progress, and reaffirms 2026 cash burn.
- product/platformNebula
Ginkgo’s autonomous cloud lab scaling in ramp mode, onboarding protocols weekly and increasing device capacity in Q3.
- government programNSF cloud lab nodes
Caltech, Northwestern, and University of Maryland commissioned autonomous labs under NSF investment; MIT Media Lab grant supports a cloud lab build.
